Evidence map›Paper›PMID 39429192›Full record

ArticleTechnology in cancer research & treatment

The MiR-200c/FOXP3 Network: A Promising Biomarker for Predicting Trastuzumab Response in HER2-Positive Breast Cancer.

Mohamed S Othman, Mohamed Tharwat Elabbasy, Ahmed M Aref, Aya A Altaleb, Marwa Hamdy Mohammed, Doaa Atef Mohamed Soliman, Nashwa El-Khazragy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. The mechanism of ncRNA in trastuzumab resistance in HER2-positive tumors.Medical oncology (Northwood, London, England) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mohamed S OthmanDepartment of Biochemistry, College of Medicine, University of Ha'il, Ha'il, Saudi Arabia.
Mohamed Tharwat ElabbasyCollege of Medicine, University of Ha'il, Ha'il, Saudi Arabia.
Ahmed M ArefFaculty of Biotechnology, October University for Modern Sciences and Arts, Giza, Egypt.
Aya A AltalebCollege of Medicine, Gazi University, Ankara, Turkey.
Marwa Hamdy MohammedDepartment of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Doaa Atef Mohamed SolimanDepartment of Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Nashwa El-KhazragyDepartment of Clinical Pathology-Hematology and AinShams Medical Research Institute (MASRI), Faculty of Medicine, Ain Shams University, Cairo, Egypt.ORCID 0000-0001-6646-4674

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Biomarkers, TumorBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesForkhead Transcription FactorsMicroRNAsTrastuzumabAdultAgedAntineoplastic Agents, ImmunologicalDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansKaplan-Meier EstimateMiddle AgedAntineoplastic Agents, ImmunologicalBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesForkhead Transcription FactorsFOXP3 protein, humanMicroRNAsMIRN200 microRNA, humanTrastuzumabdrug resistanceFOXP3HER2-positive breast cancermetastatic breast cancermiR-200cpredictor biomarkerTrastuzumab

Identifiers

PMID39429192
PMCPMC11494628

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.